No description available.

Chemokines are small immune system proteins mediating leukocyte migration and activation, and are important in many aspects of health and diseases. Some chemokines also have the ability to block HIV-1 infection by binding to the HIV-1 co-receptors CCR5 (CC chemokine receptor 5) and CXCR4 (CXC chemokine receptor 4). The first part of this work is to determine the mechanism of action of a human herpesvirus-8 encoded viral chemokine analog vMIP-II (viral macrophage inflammatory protein-II) by characterizing its interactions with endothelial surface glycosaminoglycans (GAGs) and cell surface receptors. Nuclear magnetic resonance (NMR), mutagenesis and molecular-docking were conducted and results show that vMIP-II tightly binds glycosaminoglycans using residues distributed along one face of the protein, such as R18, R46 and R48, and that there is a shift in the GAG binding site between the monomer and dimer form of vMIP-II where the N-terminus is involved in GAG binding for the dimer. This study, for the first time, provides a model that explains the mechanism of how quaternary structure affects chemokine-GAG binding. Mutagenesis and competition binding assays were conducted to study the receptor-binding mechanism of vMIP-II. Preliminary results suggest that vMIP-II uses the same positively charged binding surface comprising R18, K45, R46 and R48 to interact with the negatively charged N-termini of CCR5 and CXCR4. NMR studies on how vMIP-II interacts with N-terminal peptides of CCR5 and CXCR4 is on-going. The second part of this work was to rationally design HIV-1 entry inhibitors based on our knowledge of the mechanisms of chemokine-receptor binding and HIV-1 cell entry. We successfully designed two chimeric HIV entry inhibitors composed of CCR5-targeting RANTES variants (5P12-RANTES and 5P14-RANTES) linked to a gp41 targeting C-peptide, C37. In in vitro assays, chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed the highest anti-viral potency yet published with IC50 values as low as 0.001 nM against certain virus strains. On human peripheral blood mononuclear cells, the chimeric inhibitors also exhibited very strong inhibition against R5-tropic and X4-tropic viruses, with IC50 values as low as 0.015 nM and 0.44 nM, respectively. A clear delivery mechanism was observed and characterized. These fully recombinant inhibitors can be easily produced at low cost and are excellent candidates for HIV microbicides.

The cyto-protective compositions and effects of antiviral Maillard reaction products (MRPs) derived from roots of Isatis indigotica F. were examined using biochemical and biophysical methods. The Maillard reaction was identified as the main source of compounds with antiviral activity, an observation which has led to the proposal of a new class of active compounds that protect cells from influenza virus infection. In the roots, arginine and glucose were revealed to be the predominant reactants for the Maillard reaction. Significant anti-influenza virus effects were demonstrated in the RIE MRPs derived from the roots (RIE refers to the ‘radix Isatidis extracts’), and in Arg-Glc MRPs which are synthesised with arginine and glucose. Arg-Glc MRPs were confirmed as suitable models for the study of the antiviral effects of the root extracts. Furthermore, RIE MRPs and Arg-Glc MRPs were found to bind to the plasma membranes of erythrocytes and MDCK cells, and altered their properties. A novel antiviral mechanism was proposed: that MRPs achieve their cyto-protective effects by binding to the cell membrane rather than by direct action on viral particles. To validate the proposed mechanism, the interaction between MRPs and membrane lipids was investigated by biophysical experiments with phospholipids bilayers. Arg-Glc MRPs affected the rigidity of lipid packing in monolayers and bilayers, while RIE MRPs enhanced the fluidity. Both types of MRPs inserted into the hydrophobic core of bilayers, to differing extents, and induced the stabilisation or destabilisation of bilayers in a concentrationdependent manner. At certain concentrations, MRPs prevented the lamellar structure of bilayers from being destabilised by a viral fusion peptide, improved the lipid order and thereby inhibited cell-virus membrane fusion. The mechanism of the anti-influenza virus activity of RIE was therefore correlated to the interaction between MRPs and phospholipid bilayers, an integral component of the plasma membrane.

O entendimento em nível molecular da interação tanto de vírus causadores de doenças (ou parte deles, como proteínas e peptídeos) quanto de moléculas candidatas a fármacos, é de suma importância para a terapia e tratamento de doenças. Neste trabalho, utilizamos técnicas biofísicas e bioquímicas para o estudo da interação entre miméticos de membrana e dois grupos de pequenas moléculas. A primeira relacionada a uma doença, o peptídeo de fusão da Dengue, sequência putativa da glicoproteína E do vírus da Dengue, e que se conserva entre outros flavivírus, como o vírus da Zika. Já o segundo grupo é formado por compostos de coordenação de cobre, Fenantrolina e os dipeptídeos Ala-Gly e Ala-Phe: Cu(L-dipeptídeo)(Fenantrolina), e que são potenciais candidatos a fármacos antitumorais. Nossos resultados mostram que as moléculas de ambos os grupos são capazes de interagir e modificar as propriedades do sistema mimético de membrana. Indicando que, por um lado, se pode pensar em estratégias de bloqueio da interação para evitar infecção pelo vírus e, por outro lado, se pode usar nossos resultados para melhor planejar formas de potencializar a interação em mecanismos de entrega de fármaco e/ou de difusão pela barreira física representada pelo sistema de membranas da célula tumoral / The understanding at the molecular level of the interaction of both disease-causing viruses (or part thereof, such as proteins and peptides) and drug-candidate molecules is of paramount importance for the therapy and treatment of such diseases. In this work, we use biophysical techniques to study the interaction between membrane mimetics and two groups of small molecules. The first one is related to a disease, the Dengue fusion peptide, putative sequence of Dengue virus glycoprotein E, which is conserved among other flaviviruses, such as the Zika virus. The second group consists of coordination compounds of copper, Phenantroline and the dipeptides Ala-Gly and Ala-Phe: Cu (L-dipeptide) (phenanthroline), which are potential candidates for antitumor drugs. Our results show that the molecules form both groups are capable of interacting and modifying the physic-chemical properties of the mimetic membrane system. This indicates that, on one hand, one can think in strategies of blocking the interaction to avoid virus infection and, on the other hand, one can use our results to improve membrane interaction in drug delivery mechanisms and/or for facilitating diffusion through the physical barrier represented by the membranes in tumor cells

O entendimento em nível molecular da interação tanto de vírus causadores de doenças (ou parte deles, como proteínas e peptídeos) quanto de moléculas candidatas a fármacos, é de suma importância para a terapia e tratamento de doenças. Neste trabalho, utilizamos técnicas biofísicas e bioquímicas para o estudo da interação entre miméticos de membrana e dois grupos de pequenas moléculas. A primeira relacionada a uma doença, o peptídeo de fusão da Dengue, sequência putativa da glicoproteína E do vírus da Dengue, e que se conserva entre outros flavivírus, como o vírus da Zika. Já o segundo grupo é formado por compostos de coordenação de cobre, Fenantrolina e os dipeptídeos Ala-Gly e Ala-Phe: Cu(L-dipeptídeo)(Fenantrolina), e que são potenciais candidatos a fármacos antitumorais. Nossos resultados mostram que as moléculas de ambos os grupos são capazes de interagir e modificar as propriedades do sistema mimético de membrana. Indicando que, por um lado, se pode pensar em estratégias de bloqueio da interação para evitar infecção pelo vírus e, por outro lado, se pode usar nossos resultados para melhor planejar formas de potencializar a interação em mecanismos de entrega de fármaco e/ou de difusão pela barreira física representada pelo sistema de membranas da célula tumoral / The understanding at the molecular level of the interaction of both disease-causing viruses (or part thereof, such as proteins and peptides) and drug-candidate molecules is of paramount importance for the therapy and treatment of such diseases. In this work, we use biophysical techniques to study the interaction between membrane mimetics and two groups of small molecules. The first one is related to a disease, the Dengue fusion peptide, putative sequence of Dengue virus glycoprotein E, which is conserved among other flaviviruses, such as the Zika virus. The second group consists of coordination compounds of copper, Phenantroline and the dipeptides Ala-Gly and Ala-Phe: Cu (L-dipeptide) (phenanthroline), which are potential candidates for antitumor drugs. Our results show that the molecules form both groups are capable of interacting and modifying the physic-chemical properties of the mimetic membrane system. This indicates that, on one hand, one can think in strategies of blocking the interaction to avoid virus infection and, on the other hand, one can use our results to improve membrane interaction in drug delivery mechanisms and/or for facilitating diffusion through the physical barrier represented by the membranes in tumor cells

All challenges associated with influenza A viruses including antigenic variation in hemagglutinin (HA) and neuraminidase (NA), the evolving drug resistance and the drawbacks of current vaccines hinder our ability to control this constant threat. Furthermore, gene reassortment as well as the direct transmission of highly pathogenic avian viruses to humans can result in an occasional emergence of novel influenza strains with devastating pandemic potential. Therefore, it is crucial to investigate alternative approaches to better control these viruses and to develop new prophylactic and treatment options. Targeting highly conserved epitopes or antigens among the different subtypes of influenza A virus could offer protection against broad range of influenza viruses, including emerging strains. In my research, I have investigated the potential of broadly neutralizing antibodies against HA and conducted mechanistic study of a prototype vaccine based on the highly conserved nucleoprotein (NP). We recently found that the 14 amino acids of the amino-terminus of the fusion peptide of influenza HA2 subunit is the only universally conserved sequence in all HA subtypes of influenza A and the two lineages of influenza B viruses. Here, I show that universal antibodies targeting this linear sequence in the viral HA (Uni-1 antibodies) can cross-neutralize multiple subtypes of influenza A virus by inhibiting the pH-dependant fusion of viral and cellular membranes. It is noted that the influenza NP is a highly conserved antigen and has the potential to induce heterosubtypic immunity against divergent subtypes of influenza A virus. However, NP-based vaccination only affords weak protective immunity compared to HA. This is mostly due to the non-sterilizing immunity induced by NP. Using CD40 ligand (CD40L), a key regulator of the immune system, as both a targeting ligand and a molecular adjuvant, I show that single immunization with recombinant adenovirus carrying a fused gene encoding the secreted NP-CD40L fusion protein provided robust and long-lasting protection against influenza in normal mice. It enhanced both B-cell and T-cell responses and augmented the role of both NP-specific antibodies and CTLs in protection. Importantly, it afforded effective protection in CD40L and CD4 deficient mice, confirming that the induced protection is CD40L-mediated and CD4+ T cell-independent. The rapid evolution of the influenza A viruses necessitates the development of new alternatives to contain this medically important pathogen. The results of these studies could significantly contribute to future vaccine development and avert the necessity of yearly vaccine updates.

All challenges associated with influenza A viruses including antigenic variation in hemagglutinin (HA) and neuraminidase (NA), the evolving drug resistance and the drawbacks of current vaccines hinder our ability to control this constant threat. Furthermore, gene reassortment as well as the direct transmission of highly pathogenic avian viruses to humans can result in an occasional emergence of novel influenza strains with devastating pandemic potential. Therefore, it is crucial to investigate alternative approaches to better control these viruses and to develop new prophylactic and treatment options. Targeting highly conserved epitopes or antigens among the different subtypes of influenza A virus could offer protection against broad range of influenza viruses, including emerging strains. In my research, I have investigated the potential of broadly neutralizing antibodies against HA and conducted mechanistic study of a prototype vaccine based on the highly conserved nucleoprotein (NP). We recently found that the 14 amino acids of the amino-terminus of the fusion peptide of influenza HA2 subunit is the only universally conserved sequence in all HA subtypes of influenza A and the two lineages of influenza B viruses. Here, I show that universal antibodies targeting this linear sequence in the viral HA (Uni-1 antibodies) can cross-neutralize multiple subtypes of influenza A virus by inhibiting the pH-dependant fusion of viral and cellular membranes. It is noted that the influenza NP is a highly conserved antigen and has the potential to induce heterosubtypic immunity against divergent subtypes of influenza A virus. However, NP-based vaccination only affords weak protective immunity compared to HA. This is mostly due to the non-sterilizing immunity induced by NP. Using CD40 ligand (CD40L), a key regulator of the immune system, as both a targeting ligand and a molecular adjuvant, I show that single immunization with recombinant adenovirus carrying a fused gene encoding the secreted NP-CD40L fusion protein provided robust and long-lasting protection against influenza in normal mice. It enhanced both B-cell and T-cell responses and augmented the role of both NP-specific antibodies and CTLs in protection. Importantly, it afforded effective protection in CD40L and CD4 deficient mice, confirming that the induced protection is CD40L-mediated and CD4+ T cell-independent. The rapid evolution of the influenza A viruses necessitates the development of new alternatives to contain this medically important pathogen. The results of these studies could significantly contribute to future vaccine development and avert the necessity of yearly vaccine updates.

A dengue é uma doença viral infecciosa predominante de regiões tropicais e subtropicais que atinge cerca de 400 milhões de pessoas anualmente. Possui quatro sorotipos diferentes do vírus (DEN.I-IV), de modo que a reinfecção por um novo sorotipo pode causar um quadro mais grave da doença: a dengue hemorrágica e a síndrome do choque da dengue. Durante o processo de infecção o vírus passa por duas etapas importantes: a primeira é a entrada dentro da célula hospedeira; a segunda etapa, é a fusão da bicamada lipídica viral com a membrana do endossomo. Ambas as etapas são mediadas pela Glicoproteína E, e é nessa proteína que se encontra o peptídeo putativo de fusão. O peptídeo possui elevado grau de homologia entre todos os membros de Flaviviridae. Neste trabalho, avaliamos a interação entre o peptídeo de fusão da dengue II, modificado, e membranas modelo através da combinação de técnicas experimentais (Fluorescência, SAXS, DSC e Cryo-TEM) e simulações por Dinâmica Molecular. Avaliamos a capacidade do peptídeo DEN.II 88-123 em induzir a fusão de vesículas de DMPC, DMPC:DMPG (4:1), bem como de alterar as propriedades das bicamadas lipídicas. Buscamos ainda compreender como sua estrutura secundária é afetada pela interação com as bicamadas lipídicas e qual o posicionamento dele em relação à membrana. Conseguimos mostrar que o peptídeo é capaz de alterar a cooperatividade lipídica das membranas conforme a composição lipídica e isso pode ser relacionado a capacidade de induzir fusão entre vesículas. Entretanto, os resultados de dinâmica molecular revelaram que o peptídeo não foi capaz de induzir mudanças em parâmetros estruturais tais como: área por lipídio, espessura e parâmetro de ordem da bicamada. Durante a interação o peptídeo ficou preferencialmente na superfície da bicamada, com inserção do resíduo hidrofóbico triptofano entre as cadeias alifáticas. O peptídeo não apresentou uma conformação estrutural preferencial, embora tenha apresentado pequenas proporções de formação de folha- e -hélice. Em conjunto, esses resultados podem auxiliar na compreensão do modo de ação dos peptídeos de fusão. / Dengue fever is viral infectious disease widespread in tropical and subtropical areas that infects nearly 400 million people annually. There are four different virus serotypes (DEN.I-IV) so that a reinfection by a different serotype may lead to a more severe case of the disease: dengue hemorrhagic fever and the dengue shock syndrome. During the infection cycle, the virus has two important steps: the first one is the entry in the host cell; the second one, is the fusion between the viral lipid bilayer and the endosomal membrane. Both steps are mediated by the E Glycoprotein, that is the host of the putative fusion peptide. The fusion peptide has a high degree of homology among the members of the Flaviviridae. In this work, we evaluated the interaction between modified dengue fusion peptide and model membranes through the combination of experiments (fluorescence, SAXS, DSC and Cryo-TEM), and Molecular Dynamics simulations. We evaluated the capacity of the DEN.II 88-123 peptide to promote fusion between vesicles composed by DMPC, DMPC:DMPG (4:1), as well as the ability to perturb the lipid bilayer properties. Moreover, we seek to understand how the secondary structure is affected by interaction with the model membranes and the peptide position in the membrane. We showed that the peptide is able to change the membrane lipid cooperativity depending on the lipid composition and it may be related to the capacity of fusion induction between vesicles. However, the results revealed that the peptide does not induce changes in the structural parameters such as area per lipid, thickness and bilayer order parameter. The peptide binds to the surface of the lipid bilayer with the insertion of the tryptophan residue into the region of aliphatic chains. The peptide did not have a preferential secondary structure, although it presented a low percentage of -sheet and -helice conformation. Together, these results may help to understand the mode of action of fusion peptides.

A dengue é uma doença viral infecciosa predominante de regiões tropicais e subtropicais que atinge cerca de 400 milhões de pessoas anualmente. Possui quatro sorotipos diferentes do vírus (DEN.I-IV), de modo que a reinfecção por um novo sorotipo pode causar um quadro mais grave da doença: a dengue hemorrágica e a síndrome do choque da dengue. Durante o processo de infecção o vírus passa por duas etapas importantes: a primeira é a entrada dentro da célula hospedeira; a segunda etapa, é a fusão da bicamada lipídica viral com a membrana do endossomo. Ambas as etapas são mediadas pela Glicoproteína E, e é nessa proteína que se encontra o peptídeo putativo de fusão. O peptídeo possui elevado grau de homologia entre todos os membros de Flaviviridae. Neste trabalho, avaliamos a interação entre o peptídeo de fusão da dengue II, modificado, e membranas modelo através da combinação de técnicas experimentais (Fluorescência, SAXS, DSC e Cryo-TEM) e simulações por Dinâmica Molecular. Avaliamos a capacidade do peptídeo DEN.II 88-123 em induzir a fusão de vesículas de DMPC, DMPC:DMPG (4:1), bem como de alterar as propriedades das bicamadas lipídicas. Buscamos ainda compreender como sua estrutura secundária é afetada pela interação com as bicamadas lipídicas e qual o posicionamento dele em relação à membrana. Conseguimos mostrar que o peptídeo é capaz de alterar a cooperatividade lipídica das membranas conforme a composição lipídica e isso pode ser relacionado a capacidade de induzir fusão entre vesículas. Entretanto, os resultados de dinâmica molecular revelaram que o peptídeo não foi capaz de induzir mudanças em parâmetros estruturais tais como: área por lipídio, espessura e parâmetro de ordem da bicamada. Durante a interação o peptídeo ficou preferencialmente na superfície da bicamada, com inserção do resíduo hidrofóbico triptofano entre as cadeias alifáticas. O peptídeo não apresentou uma conformação estrutural preferencial, embora tenha apresentado pequenas proporções de formação de folha- e -hélice. Em conjunto, esses resultados podem auxiliar na compreensão do modo de ação dos peptídeos de fusão. / Dengue fever is viral infectious disease widespread in tropical and subtropical areas that infects nearly 400 million people annually. There are four different virus serotypes (DEN.I-IV) so that a reinfection by a different serotype may lead to a more severe case of the disease: dengue hemorrhagic fever and the dengue shock syndrome. During the infection cycle, the virus has two important steps: the first one is the entry in the host cell; the second one, is the fusion between the viral lipid bilayer and the endosomal membrane. Both steps are mediated by the E Glycoprotein, that is the host of the putative fusion peptide. The fusion peptide has a high degree of homology among the members of the Flaviviridae. In this work, we evaluated the interaction between modified dengue fusion peptide and model membranes through the combination of experiments (fluorescence, SAXS, DSC and Cryo-TEM), and Molecular Dynamics simulations. We evaluated the capacity of the DEN.II 88-123 peptide to promote fusion between vesicles composed by DMPC, DMPC:DMPG (4:1), as well as the ability to perturb the lipid bilayer properties. Moreover, we seek to understand how the secondary structure is affected by interaction with the model membranes and the peptide position in the membrane. We showed that the peptide is able to change the membrane lipid cooperativity depending on the lipid composition and it may be related to the capacity of fusion induction between vesicles. However, the results revealed that the peptide does not induce changes in the structural parameters such as area per lipid, thickness and bilayer order parameter. The peptide binds to the surface of the lipid bilayer with the insertion of the tryptophan residue into the region of aliphatic chains. The peptide did not have a preferential secondary structure, although it presented a low percentage of -sheet and -helice conformation. Together, these results may help to understand the mode of action of fusion peptides.

Quelques régions stables ont été découvertes sur les gp d’env du VIH-1 contre lesquelles des patients produisent des anticorps neutralisants. Les épitopes les plus prometteurs se trouvent dans la MPER et sont probablement exposés durant la fusion. Alors que les peptides isolés à partir de cette région ne sont pas parvenus à induire une réaction immunogène neutralisante, des études antérieures suggèrent que la membrane lipidique joue un rôle dans la structuration des antigènes et dans la réponse immunogénique.C’est pourquoi nous étudions la structure de ces épitopes. Cela nécessite leur surexpression, leur purification et leur reconstitution dans des liposomes. Une étude de CD montre qu’ils pourraient changer de conformation, cela sera confirmé par RMN. En outre, leur immunogénicité sera vérifiée par vaccination des souris. En plus, nous trouvons que le cholestérol peut modifier l’orientation des peptides englobant le motif CRAC de la gp41. / A few stable regions have been discovered on the HIV-1 env gp against which some patients produce neutralizing antibodies. The most promising ones are located in the MPER and are probably exposed transiently during the fusion. Whereas the peptides isolated from this region failed to induce immunogenic response, previous studies suggest the lipid membrane plays a role in antigens structure and in the immunogenic response.That is why we investigate the structure of these épitopes in membrane models. This requires the production of these épitopes by bacterial overexpression, their purification and their reconstitution in liposomes. A CD study shows that they could undergo a conformational change; this will be confirmed by NMR. Also their immunogenicity will be checked by mice immunization. In addition, we find that cholesterol could change the orientation of peptides encompassing a gp41 CRAC motif.